Lauren M. Green | Authors


Web-Based Tool for Symptom Reporting Leads to Longer Survival in Advanced Cancer Patients

June 16, 2017

Patients receiving treatment for metastatic cancer who used a web-based tool to report their symptoms either while at home or during clinic visits lived on average 5 months longer than their counterparts who had standard symptom monitoring.

Responses Stimulated Across All Tumor Types Harboring TRK Fusions With Larotrectinib

June 06, 2017

Larotrectinib (LOXO-101), the novel pan-TRK inhibitor, induced responses in 3 out of 4 patients with a TRK fusion–positive solid tumor, according to findings presented in a press conference June 3 at the 2017 ASCO Annual Meeting.

Five-Year Survival Rate 16% With Nivolumab in NSCLC, Follow-Up Data Shows

April 06, 2017

According to 5-year follow-up data from the CA209-003 study, long-term survival in patients with metastatic non–small cell lung cancer (NSCLC) who received the immune checkpoint inhibitor nivolumab (Opdivo) has proven to be much higher than expected, with 16% of patients surviving after 5 years.